The VISAGE consortium's efforts coincide with a push in Germany to allow DNA phenotyping and biogeographical ancestry testing in criminal investigations.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The firm will launch two new analysis modules for its Genetic Information Management Suite next year, in addition to a new pharmacogenomics mobile application.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
